We had a great time in San Francisco this week huddling around the Westin St. Francis for J.P. Morgan's 30th Healthcare Conference. Mark Hollmer gave us a fly-on-the-wall take on the mood Wednesday. John Carroll and Ryan McBride joined Mark recapping "mixed feelings" biotechnology executives are starting the year with.
We also set a mission to meet with the newsmakers driving drug and device development. Here's a quick run-down of some of the players our editorial team spoke with, complete with links to their J. P. Morgan slide show page.
Richard Pops Chairman and CEO |
Alkermes | EDT acquisition, Risperdal, Bydureon, CNS pipeline |
Olav Hellebø CEO |
Clavis Pharma | CP-4126, pancreatic cancer, gemcitabine |
Chuck Bramlage CEO |
Pearl Therapeutics | COPD, midstage PT003 studies, partnerships |
Charles Carignan President and CEO |
NinePoint Medical | Nvision VLE 510(k) clearance, high-resolution imaging, startups |
Jim Mullen CEO |
Patheon | Manufacturing fundamentals, Phase I molecules, consolidation |
Francois Nader President and CEO |
NPS Pharmaceuticals | Injectable orphan drugs, commercialization shift |
Noubar Afeyan CEO |
Flagship Ventures | Exclusive: $270m fund | New generation of drug discovery |
Dave Rosa CEO |
Sunshine Heart | Implantable balloon counter-pulsation device, pivotal trial launch |
Andreas Sundquist Co-founder and CEO |
DNAnexus | Google Ventures, genomic data platformization |
Steven Tregay CEO |
Forma Therapeutics | Big pharma collaborations, small-molecule attacks on tumors |
Tuan Ha-Ngoc President and CEO |
Aveo Pharmaceuticals | Positive tivozanib data, renal cell carcinoma |
Roger Tung President and CEO |
Concert Pharmaceuticals | Deuterium drug platform, CTP-499, diabetic nephropathy |
James E. Brown CEO |
Durect | Phase III Posidur abdominal data |
Editor's Note: FierceBiotech won't be published Monday, Jan. 16, in honor of Martin Luther King Jr. Day. We will return to our regular schedule Tuesday, Jan. 17.